Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q5XUX0

UPID:
FBX31_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q5XUX0; Q5K680; Q8WYV1; Q96D73; Q9UFV4

BACKGROUND:
The F-box only protein 31 is a crucial component of the SCF ligase complex, essential for DNA damage-induced G1 arrest. It targets phosphorylated cyclin-D1 for proteasomal degradation, effectively stopping cell cycle progression in G1. This mechanism underscores its significance as a potential tumor suppressor.

THERAPEUTIC SIGNIFICANCE:
Linked to Intellectual developmental disorder, autosomal recessive 45, F-box only protein 31's dysfunction manifests in significant intellectual disability and distinct facial dysmorphisms. Exploring this protein's function could lead to innovative treatments for the disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.